新股消息 | 药明巨诺计划周四就香港IPO寻求上市批准
彭博报道,据IFR引述接近交易的人士报道,细胞疗法公司JW Therapeutics(药明巨诺)计划周四就约2亿至3亿美元香港IPO申请上市批准。
高盛和瑞银是此次IPO的联席保荐人。
JW Therapeutics(药明巨诺)由Juno Therapeutics和药明康德于2016年在上海成立。
根据初步招股书,JW Therapeutics(药明巨诺)是全球领先的临床阶段细胞治疗平台公司,主打候选产品elmacabtagene autoleucel(「relma-cel」)是针对复发或难治(「r/r」)B细胞淋巴瘤的抗CD19 CAR-T疗法,且国家药监局已于2020年6月受理审查将relmacel用作DLBCL三线疗法的新药申请。Relma-cel有望成为中国首个获批的一类生物制品CAR-T疗法,并有望成为同类最佳CAR-T疗法。
uSMART早前报道:
《新股消息 | 药明康德、淡马锡投资的JW(Cayman)向港交所递表》
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.